Concord Biotech Limited (NSE: CONCORDBIO)

Market Cap	228.18B
Revenue (ttm)	10.86B
Net Income (ttm)	3.28B
Shares Out	104.62M
EPS (ttm)	31.35
PE Ratio	69.57
Forward PE	52.83
Dividend	8.75 (0.40%)
Ex-Dividend Date	Jun 21, 2024

Volume	79,186
Open	2,199.00
Previous Close	2,197.65
Day's Range	2,135.10 - 2,220.00
52-Week Range	1,289.00 - 2,664.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About Concord Biotech

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1984
• Employees: 1,377
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: CONCORDBIO

Financial Performance

In 2023, Concord Biotech's revenue was 10.17 billion, an increase of 19.20% compared to the previous year's 8.53 billion. Earnings were 3.08 billion, an increase of 28.33%.